MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation
about
Current challenges and novel treatment strategies in double hit lymphomasMYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical managementThe MYC/miR-17-92 axis in lymphoproliferative disorders: A common pathway with therapeutic potentialNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewDouble-Hit Lymphoma: Practicing in a Data-Limited Setting.Rate of primary refractory disease in B and T-cell non-Hodgkin's lymphoma: correlation with long-term survival.A Case of Advanced Primary Thyroid Double-Hit B Cell Lymphoma in Which Complete Remission has been Maintained After High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation Performed During the Second Remission, with a ReviewEarly failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantationComplete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survivalBiological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma.Association between BACH2 expression and clinical prognosis in diffuse large B-cell lymphoma.GSTT1 deletion is related to polycyclic aromatic hydrocarbons-induced DNA damage and lymphoma progressionC-MYC aberrations as prognostic factors in diffuse large B-cell lymphoma: a meta-analysis of epidemiological studiesAlisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2.Aggressive B-cell lymphomas: how many categories do we need?Genetic lesions in diffuse large B-cell lymphomasFrontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.The prognosis of MYC translocation positive diffuse large B-cell lymphoma depends on the second hit.Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancersIdentification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers.Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses.Diffuse large B cell lymphoma: molecular targeted therapy.The role of allogeneic haematopoietic progenitor cell transplantation in patients with diffuse large B-cell non-Hodgkin lymphomas (DLBCL).The impact of MYC rearrangements and "double hit" abnormalities in diffuse large B-cell lymphoma.Diffuse large B-cell lymphoma-treatment approaches in the molecular era.Relapsed/refractory diffuse large B-cell lymphoma: review of the management of transplant-eligible patients.MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.In pursuit of a moving target: nanotherapeutics for the treatment of non-Hodgkin B-cell lymphoma.Double hit lymphoma - a case of unusual response after sequential aggressive chemotherapy and review of the literature.The transcription factor ETS1 in lymphomas: friend or foe?Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies.Improving survival and preventing recurrence of diffuse large B-cell lymphoma in younger patients: current strategies and future directionsClinical significance of co-expression of MYC and BCL2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapy.Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.MYC rearrangements are useful for predicting outcomes following rituximab and chemotherapy: multicenter analysis of Japanese patients with diffuse large B-cell lymphoma.MYC status determination in aggressive B-cell lymphoma: the impact of FISH probe selection.CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial.
P2860
Q26770385-5E6F18DA-20AE-41A2-8016-13189348EEDCQ26785379-768E579F-54C5-4062-8997-C4B1C5A81BD4Q26797469-E449AF7F-198F-4EB1-8F74-A9957D26573EQ27304386-AA4E1E63-AE72-4ED7-BC17-F034B3D3EBB1Q31056413-06894263-2528-4904-8EA1-A2E97080171FQ34257135-D5BD1A7D-429D-493B-8F13-692BEA3056EDQ34316137-0B96B417-80F7-47F3-BA6E-3A5234B36EBFQ34325329-48E5495D-E1AA-403F-9EF1-44FD93CE4D9DQ34918948-23A149CB-1D94-405D-B6D2-5ABD1F1BEA5FQ35030096-C054CB5B-2A9A-4ECC-9C0C-D2E8BEA14823Q35051455-BAAB41C7-7A16-482C-BA64-327192D5C042Q35107033-9654E6A9-B98E-41F9-A00E-5355B6683D99Q35150618-1207A7ED-8377-4B48-897B-151B10F9DD04Q35180822-129956CA-9260-4EEF-B916-FE467DDD712EQ35527893-078570FA-2171-4531-927C-3321414B38D9Q35974341-6620D667-64A6-4C82-9EF1-0A77D1DFC66AQ36192439-250EBC6B-D772-4D15-B7E5-28B550BB563EQ37024999-8EAF24FE-F285-4001-A783-34EC19106BABQ37031640-AC75E9D2-7257-48B3-A059-7E2881CBCCC7Q37621025-4BA3B3E0-DD3B-4BFF-8D8F-80ECDE52C061Q37696308-2FC7AF3B-5EA0-4C56-B9DA-60491F927143Q37708919-7FD9A7E0-B922-4FCD-9EC1-5788933531D8Q38053983-9D1E4F6C-BD7D-4272-A4C2-4EDDACED7D0FQ38074021-61B24B74-03D4-4858-913B-3FD46E7F9B6EQ38124735-EDFFC825-463A-4598-B3DD-6DC46D9B468AQ38161760-3A56E3F8-CCB1-47F6-A747-57F3ADFCD3ECQ38210641-7A74BF2F-791D-43C2-923E-7E8DD516527EQ38233772-6637E4C3-05AC-43D3-8ADC-A799954C737AQ38253121-B8F920F5-CB20-4BF9-BEFF-2FE1A4D9AF64Q38261916-B41CB360-3B36-4CA0-A3E2-2E072B2FEFA2Q38264349-F32C2C78-35A7-42B6-B28C-9450E09B3881Q38376595-2717D02C-7257-413F-A21D-66EAD1762B28Q38642477-F0C035BC-A214-4716-9B81-1157935B3E9EQ39158429-41EC8AB8-95E7-4BBC-BB88-E2CA69ECCC64Q39436199-2F49F787-9A95-4313-B74E-7BEBF5F0A7A7Q41339798-EEEDFF9F-0B3E-40CD-87F6-22A0F606CF5AQ41896892-84BC09D9-EE54-4528-A669-49C6178BC19CQ43945141-03E80444-3C99-45A1-A669-2AAA34F4AEA2Q46017773-C9890D76-082B-4E52-83C0-A45ACBA9E5D3Q47109026-8EE705E5-755B-4EC1-A823-6ADCEA7C5582
P2860
MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 March 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
MYC+ diffuse large B-cell lymp ...... gous stem cell transplantation
@en
MYC+ diffuse large B-cell lymp ...... ous stem cell transplantation.
@nl
type
label
MYC+ diffuse large B-cell lymp ...... gous stem cell transplantation
@en
MYC+ diffuse large B-cell lymp ...... ous stem cell transplantation.
@nl
prefLabel
MYC+ diffuse large B-cell lymp ...... gous stem cell transplantation
@en
MYC+ diffuse large B-cell lymp ...... ous stem cell transplantation.
@nl
P2093
P2860
P1433
P1476
MYC+ diffuse large B-cell lymp ...... gous stem cell transplantation
@en
P2093
Andreas Rosenwald
Catherine Thieblemont
Christer Sundstrom
Christian Gisselbrecht
Dominique Bron
Edouard Hirchaud
Hans-Ullrich Voelker
Jean Soulier
Josette Briere
Loic Ysebaert
P2860
P304
P356
10.1182/BLOOD-2012-01-406033
P407
P577
2012-03-09T00:00:00Z